STATEMENT OF USE - TO EXAMINER
to examiner
on 05 Sep 2023
Last Applicant/ Owned by
750 Royal Oaks Dr.
Monrovia
CA
91016
Serial Number
90287671 filed on 29th Oct 2020
Registration Number
N/A
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
INVIZYNE
Fragrances; terpenes for use in essential oils Biofuels; fuels, biofuels and biodiesels based on energy-producing organic compounds, namely, terpenes, isoprenoids, alcohols, fatty acids, esters, alkanes, and alkenes Pharmaceuticals, namely, alcohols, esters, alkaloids, polyketides, steroids, isoprenoids, and non-ribosomal peptides, for use the treatment of pain, neuropathic pain, cancer pain, on Read More
Classification Information
Class [030]
Staple Food Products
Flavor enhancers for use in food and beverage products
First Use Date in General
25th May 2023
First Use Date in Commerce
25th May 2023
Class [005]
Pharmaceutical Products
Pharmaceuticals, namely, alcohols, esters, alkaloids, polyketides, steroids, isoprenoids, and non-ribosomal peptides, for use the treatment of pain, neuropathic pain, cancer pain, oncology, cancer symptoms, psychiatric illnesses, neurodegenerative diseases, multiple sclerosis, spinal cord injury, bladder disfunction, peripheral neuropathy, spasticity, perioperative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, hypoxic-ischaemic encephalopathy, symptoms of neurogenic disorders, movement disorders, essential tremors, psychotic disorders, diseases of the central nervous system, stroke and head injuries, motion sickness and chemically induced sickness, post-traumatic stress disorder, obesity, obesity associated with Type II Diabetes, bulimia, schizophrenia, Crohn's disease, Alzheimer's disease, bone disorders, inflammatory disorders, sleep and sleep disorders, and drug, alcohol, and nicotine abuse, epilepsy, convulsions, seizures, Dravet syndrome, Lennox-Gastaut syndrome, intractable childhood epilepsy with generalized tonic-clonic seizures, generalized epilepsy with febrile seizures plus, Doose syndrome, chromosome disorders, and metabolic disorders; anti-inflammatories; analgesics; nutraceuticals for use as a dietary supplement; dietary and nutritional supplements; none of the foregoing containing CBD, cannabinoids or tryptamines
First Use Date in General
25th May 2023
First Use Date in Commerce
25th May 2023
Class [004]
Lubricant and Fuel Products
Biofuels; fuels, biofuels and biodiesels based on energy-producing organic compounds, namely, terpenes, isoprenoids, alcohols, fatty acids, esters, alkanes, and alkenes
First Use Date in General
25th May 2023
First Use Date in Commerce
25th May 2023
Class [003]
Cosmetics and Cleaning Products
Fragrances; terpenes for use in essential oils
First Use Date in General
25th May 2023
First Use Date in Commerce
25th May 2023
Mark Details
Serial Number
No 90287671
Mark Type
No Service/Collective Mark
Attorney Docket Number
No 15041.T002US
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Design Code(s)
24.15.25 -
Other arrows
Legal History
| Status Date | Action Taken |
|---|---|
| 16th Jan 2024 | ASSIGNED TO EXAMINER |
| 29th Sep 2023 | ASSIGNED TO EXAMINER |
| 05th Sep 2023 | STATEMENT OF USE PROCESSING COMPLETE |
| 31st Aug 2023 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 24th Aug 2023 | TEAS STATEMENT OF USE RECEIVED |
| 24th Aug 2023 | USE AMENDMENT FILED |
| 23rd Aug 2023 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| 23rd Aug 2023 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| 23rd Aug 2023 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| 23rd Aug 2023 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |